Compare INVE & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | ASMB |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 442.9M |
| IPO Year | 1997 | 2010 |
| Metric | INVE | ASMB |
|---|---|---|
| Price | $3.94 | $28.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.50 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 223.7K | 153.5K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.08 | $13.80 |
| 52 Week High | $5.30 | $39.71 |
| Indicator | INVE | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 49.44 |
| Support Level | $3.23 | $26.50 |
| Resistance Level | $5.30 | $31.11 |
| Average True Range (ATR) | 0.28 | 1.79 |
| MACD | -0.12 | -0.22 |
| Stochastic Oscillator | 15.94 | 39.25 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.